Corneal neovascularization is the abnormal growth of blood vessels into the cornea and can put vision at risk. The cornea normally does not contain blood vessels (is avascular), but certain conditions including trauma, infection, and inflammation can cause the growth of vessels into the cornea. 

This study is using bevacizumab (Avastin). Avastin works by inhibiting the action of a molecule called vascular endothelial growth factor (VEGF). VEGF is a molecule that binds to certain cells to stimulate new blood vessel formation. The use of Avastin is intended to prevent the formation of new blood vessels in the cornea.

The purpose of this study is to determine the efficacy and safety of Avastin used in an eye drop in patients with corneal neovascularization. This study is enrolling concurrently with a study using a drug called Lucentis. Patients will be enrolled on an alternating schedule between Avastin and Lucentis treatments.

This is a 24 week study consisting of up to 7 office visits. During some of these visits pictures will be taken of the cornea using a slit lamp microscope.